검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | rHuPH20 |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Malignant Solid Tumor |
Overview Indication | Malignant Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target immune checkpoint inhibitor pathway |
MoA Biomarker | biomarker measures of immune function (pretreatment and on-treatment peripheral blood and tumor biopsies) |
PK/PD Half-life | 47 h |
PK/PD Species | Minipig, Pig |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Minipig, Pig |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs.. Subcutaneous (SC) administration of therapeutic antibodies offers advantages over intravenous (IV) delivery, including improved patient convenience and a pharmacokinetic (PK) profile characterized by lower peak plasma concentrations without affecting… |
Clinical Primary efficacy | ORR 40.4% |
Clinical ORR | 40.4% |
Clinical PFS | 6.05 |
Clinical OS | 9.59 |
Clinical Result source | ClinicalTrials.gov NCT01839487 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | rHuPH20 |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Malignant Solid Tumor |
Overview Indication | Malignant Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target immune checkpoint inhibitor pathway |
MoA Biomarker | biomarker measures of immune function (pretreatment and on-treatment peripheral blood and tumor biopsies) |
PK/PD Half-life | 47 h |
PK/PD Species | Minipig, Pig |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Minipig, Pig |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs.. Subcutaneous (SC) administration of therapeutic antibodies offers advantages over intravenous (IV) delivery, including improved patient convenience and a pharmacokinetic (PK) profile characterized by lower peak plasma concentrations without affecting… |
Clinical Primary efficacy | ORR 40.4% |
Clinical ORR | 40.4% |
Clinical PFS | 6.05 |
Clinical OS | 9.59 |
Clinical Result source | ClinicalTrials.gov NCT01839487 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교